Review shows immune cells may be off in vitiligo

This review looked at how certain immune cells, called regulatory T cells, work in people with vitiligo. The review did not report a specific number of patients or study settings. It found that in vitiligo patients, these calming immune cells are reduced in number and less effective in the blood. In the skin lesions, there are fewer of these cells and their function is compromised by the local inflammatory environment. The review also notes that treatments like NB-UVB light, JAK inhibitors, and low-dose IL-2 show promise in helping to restore immune balance, but this is based on the review's summary of existing research. A main reason to be careful is that the review points out the need to better integrate these findings from a whole-body perspective. Readers should understand this is a review of existing research, not a new clinical trial, and it highlights areas for future study rather than offering a new treatment.